Related references
Note: Only part of the references are listed.Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies
Xia-qing Xu et al.
ACTA PHARMACOLOGICA SINICA (2021)
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Erika Hamilton et al.
CLINICAL BREAST CANCER (2021)
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
C. Louwrens Braal et al.
DRUGS (2021)
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy
Madeline M. Cook et al.
ONCOLOGIST (2021)
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Aditya Bardia et al.
CLINICAL CANCER RESEARCH (2021)
Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review
Martina Silvestri et al.
DRUG SAFETY (2021)
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo et al.
LANCET ONCOLOGY (2021)
Role of FAT1 in health and disease
Zizhen Peng et al.
ONCOLOGY LETTERS (2021)
Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
Lucrezia Raimondi et al.
CANCERS (2021)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D. J. Slamon et al.
ANNALS OF ONCOLOGY (2021)
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer
Filipa Lynce et al.
CANCER (2021)
Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
Yassi Fallah et al.
FRONTIERS IN ONCOLOGY (2021)
CDK7 inhibitors as anticancer drugs
Georgina P. Sava et al.
CANCER AND METASTASIS REVIEWS (2020)
G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer
Masanori Oshi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M. Tolaney et al.
LANCET ONCOLOGY (2020)
Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+MCF7 Breast Cancer Cells
Lilibeth Lanceta et al.
GENES (2020)
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
Sunil Pancholi et al.
ONCOGENE (2020)
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
Anne Fassl et al.
SCIENCE ADVANCES (2020)
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Kamal Pandey et al.
CANCERS (2020)
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Neil Portman et al.
BREAST CANCER RESEARCH (2020)
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Neil A. O'Brien et al.
BREAST CANCER RESEARCH (2020)
Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
Ajay Dhakal et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2020)
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Neil Portman et al.
ENDOCRINE-RELATED CANCER (2019)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Jennifer L. Green et al.
MOLECULAR CANCER THERAPEUTICS (2019)
CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer
Shanshan Zhong et al.
ONCOTARGETS AND THERAPY (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu et al.
ACTA PHARMACEUTICA SINICA B (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Tim Kong et al.
MOLECULAR CANCER THERAPEUTICS (2019)
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Anna E. Vilgelm et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Amy S. Clark et al.
CLINICAL CANCER RESEARCH (2019)
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer
Sutima Luangdilok et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors
Claire R. Hall et al.
CANCER RESEARCH (2019)
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
Lorenzo Rossi et al.
BREAST CANCER RESEARCH (2019)
Clinical management of metastatic breast cancer (MBC) after CDK 4/6 inhibitors: A retrospective single-institution study
K. V. Giridhar et al.
CANCER RESEARCH (2019)
Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells
C. Guarducci et al.
CANCER RESEARCH (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
L. Malorni et al.
ANNALS OF ONCOLOGY (2018)
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Mary E. Klein et al.
CANCER CELL (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer
Chrysiis Michaloglou et al.
MOLECULAR CANCER THERAPEUTICS (2018)
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Mary E. Klein et al.
ONCOGENE (2018)
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
Silvia Paola Corona et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer
Karineh Petrossian et al.
Oncotarget (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial
A. van Ommen-Nijhof et al.
BMC CANCER (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
Ang Gao et al.
NATURE COMMUNICATIONS (2018)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci et al.
NPJ BREAST CANCER (2018)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Audrey Laroche-Clary et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan et al.
NATURE COMMUNICATIONS (2017)
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Svasti Haricharan et al.
CANCER DISCOVERY (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Erik S. Knudsen et al.
TRENDS IN CANCER (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Eric Raspe et al.
EMBO MOLECULAR MEDICINE (2017)
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
The sweet side of the cell cycle
Ee Phie Tan et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2017)
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
Valerie M. Jansen et al.
CANCER RESEARCH (2017)
Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome
L-A Martin et al.
CANCER RESEARCH (2017)
Abstract C198: PDK1 inhibitors SNS-229 and SNS-510 cause pathway modulation, apoptosis and tumor regression in hematologic cancer models in addition to solid tumors
Stig Hansen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
C. Lenihan et al.
CANCER RESEARCH (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Jeffrey R. Infante et al.
CLINICAL CANCER RESEARCH (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni et al.
ONCOTARGET (2016)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
Sadhna R. Vora et al.
CANCER CELL (2014)
Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer
Suganthi Chittaranjan et al.
CLINICAL CANCER RESEARCH (2014)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer
Agnieszka K. Witkiewicz et al.
CLINICAL CANCER RESEARCH (2012)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G. K. Schwartz et al.
BRITISH JOURNAL OF CANCER (2011)
Regulatory networks integrating cell cycle control with DNA damage checkpoints and double-strand break repair
Petra Langerak et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2011)
The activation of Akt/PKB signaling pathway and cell survival
G Song et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
Goserelin - A review of its use in the treatment of early breast cancer in premenopausal and perimencipausal women
SM Cheer et al.
DRUGS (2005)
The anaphase promoting complex/cyclosome is recruited to centromeres by the spindle assembly checkpoint
C Acquaviva et al.
NATURE CELL BIOLOGY (2004)
Share Paper
